Nonetheless, preclinical and clinical studies thus far suggest low-dose of T4, THRβ1-selective analogs, or liver-specific thyromimetics could potentially be novel, safe, and effective therapeutic agents against NAFLD/NASH. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatohepatitis.